Duration of sodium zirconium cyclosilicate treatment and continuation of RAASi therapy after a hyperkalaemia episode

Duration of sodium zirconium cyclosilicate treatment and continuation of RAASi therapy after a hyperkalaemia episode

Abstract Aims Renin–angiotensin–aldosterone system inhibitors (RAASi) are foundational in the management of heart failure (HF) and chronic kidney disease (CKD) but increase the risk of hyperkalaemia. To facilitate continuation of RAASi therapy, guidelines suggest managing hyperkalaemia using newer p...

Full description

Saved in:
Bibliographic Details
Main Authors: Charles V. Pollack Jr., David Arroyo, Eiichiro Kanda, Ignacio José Sánchez Lázaro, Eva Lesén, Stefan Franzén, Christen M. Gray, Anna Lipińska, Toyoaki Murohara, Anjay Rastogi
Format: Article
Language:English
Published: Wiley 2025-06-01
Series:ESC Heart Failure
Subjects:
chronic kidney disease
heart failure
hyperkalaemia
potassium binder
renin–angiotensin–aldosterone system inhibitor
sodium zirconium cyclosilicate
Online Access:https://doi.org/10.1002/ehf2.15171
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/ehf2.15171

Similar Items